Can a new Immune-Boosting pill make immunotherapy work better against Hard-to-Treat tumors?

NCT ID NCT06244992

Recruiting now Disease control Sponsor: Pyrotech Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study tests an experimental drug called PTT-936, which activates a protein (ALPK1) that may help the immune system attack cancer. The trial includes adults with advanced or metastatic solid tumors that cannot be removed by surgery. In the first part, patients receive PTT-936 alone to find a safe dose; in the second part, they receive PTT-936 combined with a standard immunotherapy (anti-PD-1/L1) to see if the combination is safe and effective. The main goals are to measure side effects and how many patients see their tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PTT-936, an experimental drug that activates the ALPK1 protein, given alone or with an anti-PD-1/L1 immunotherapy
What this could lead to: If successful, this could lead to a new treatment option that boosts the immune system's ability to fight advanced solid tumors, potentially improving response rates when combined with standard immunotherapy.
What could go wrong: This is an early-phase trial with a small number of patients, so safety and effectiveness are not yet established. The drug may cause side effects or may not work as hoped, and results may not apply to all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Contacts and locations

Show contact details

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, China
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, China

Contact Email: •••••@•••••
D&H Cancer Research Center
RECRUITING

Margate, Florida, 33063, United States
Precision NextGen Oncology and Research Center
RECRUITING

Beverly Hills, California, 90212, United States
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
The START Center
RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.